



Gp/1646 #17
DmJ
2-27-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Karl GUEGLER et al.

Art Unit: 1646

Serial No.: 09/749,589

Examiner: John D. Ulm

Filed: December 28, 2000

Atty. Docket: CL000861

For: ISOLATED HUMAN TRANSPORTER PROTEINS,
NUCLEIC ACID MOLECULES ENCODING HUMAN
TRANSPORTER PROTEINS, AND USES THEREOF

RECEIVED
FEB 13 2003
TECH CENTER 1600/2900

**Statement Regarding Duty to Disclose Information Material To Patentability Under
37 CFR 1.56 (a) and (b)**

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

No fee is due for this submission. However, the Patent and Trademark Office is authorized to charge any necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,
CELERA GENOMICS

Date: February 10, 2003

By: 
Lin Sun-Hoffman, Ph.D., Reg No. 47,983

Celera Genomics
45 West Gude Drive, C2-4#21
Rockville, MD 20850
Tel: 240-453-3067
Fax: 240-453-3084

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB-0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Used to respond to a collection of information unless it contains a valid OMB

<div style="text-align: right; font-size: small; margin-bottom: 5px;">Control number _____</div> <div style="text-align: center; font-weight: bold; margin-bottom: 10px;">Substitute for form 1449A/PTO</div> <div style="text-align: center; font-weight: bold; font-size: large; margin-bottom: 10px;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div style="text-align: center; font-style: italic; margin-bottom: 10px;">(use as many sheets as necessary)</div> <div style="display: flex; justify-content: space-between; font-size: small;"> Sheet 1 of 2 </div>	<div style="text-align: center; font-weight: bold; margin-bottom: 10px;">Complete if Known</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%; padding: 2px 5px;">Application Number</td> <td style="padding: 2px 5px;">09/749,589</td> </tr> <tr> <td style="padding: 2px 5px;">Filing Date</td> <td style="padding: 2px 5px;">December 28, 2000</td> </tr> <tr> <td style="padding: 2px 5px;">First Named Inventor</td> <td style="padding: 2px 5px;">Karl GUEGLER et al.</td> </tr> <tr> <td style="padding: 2px 5px;">Art. Unit</td> <td style="padding: 2px 5px;">1646</td> </tr> <tr> <td style="padding: 2px 5px;">Examiner Name</td> <td style="padding: 2px 5px;">John D. Ulm</td> </tr> <tr> <td style="padding: 2px 5px;">Attorney Docket Number</td> <td style="padding: 2px 5px;">CL000861</td> </tr> </table>	Application Number	09/749,589	Filing Date	December 28, 2000	First Named Inventor	Karl GUEGLER et al.	Art. Unit	1646	Examiner Name	John D. Ulm	Attorney Docket Number	CL000861
Application Number	09/749,589												
Filing Date	December 28, 2000												
First Named Inventor	Karl GUEGLER et al.												
Art. Unit	1646												
Examiner Name	John D. Ulm												
Attorney Docket Number	CL000861												


[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 2

Complete if Known

Application Number	09/749,589
Filing Date	December 28, 2000
First Named Inventor	Karl GUEGLER et al.
Group Art Unit	1646
Examiner Name	John D. Ulm
Attorney Docket Number	CL000861

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MCKNIGHT A J et al. "Molecular Cloning of F4/80, A Murine Macrophage-Restricted Cell Surface Glycoprotein with Homology to the G-Protein-Linked Transmembrane 7 Hormone Receptor Family." Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, US. Vol. 271, No. 1. January 5, 1996. Pgs. 486-489. XP000877442.	
		Ken TANIGUCHI et al. "A Human Canalicular Multispecific Organic Anion Transport (CMOAT) Gene is Overexpressed in Cisplatin-Resistant Human Cancer Cells Lines with Decreased Drug Accumulation." Cancer Research, American Association for Cancer Research, Baltimore, MD, US. Vol. 56, No. 18. September 15, 1996. Pgs. 4174-4179. XO000607845.	
		MAKOTO et al. "Molecular Cloning and Functional Expression of a Multispecific Organic Anion Transporter from Human Kidney." American Journal of Physiology: Renal, Fluid and Electrolyte Physiology, American Physiological Society. Vol. 276, No. 1 Part 2. January 1999. Pgs. F122-F128. XP002188133.	
		Hannes et al. "Mapping of five new putative anion transporter genes in human and characterization of SLC26A6, a Candidate Gene for Pancreatic Anion Exchanger." Genomics, Academic Press, San Diego, CA, US. Vol. 70, No. 1. November 15, 2000. Pgs. 102-112. XP002190710.	
		Haestbacka et al. "The Diastrophic Dysplasia Gene Encodes a Novel Sulfate Transporter: Positional Cloning by Fine-Structure Linkage Disequilibrium Mapping." Cell, Cell Press, Cambridge, MA, US. Vol. 78, No. 6. September 23, 1994. Pgs. 1073-1087. XP000571593.	
		International Search Report dated December 11, 2002.	

RECEIVED

FEB 13 2003

TECH CENTER 1600/2900

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.